APAC Diabetes Treatment Market

APAC Diabetes Treatment Market Size (2023 to 2028)

The APAC diabetes treatment market is forecasted to grow at a CAGR of 6.92% from 2023 to 2028 and will be worth USD 30.08 billion by 2028 from USD 21.53 billion in 2023.

Y-O-Y growth in the prevalence of diabetes is one of the major factors propelling the diabetes treatment market. The number of people living with diabetes increases yearly. Ninety million people will live with diabetes in Asia in 2021. In Asian countries, more than 60% of people have diabetes. An increase in diabetes can lead to heart attack, vision loss, leg cutting in the infected area, damage to a blood vessel, and strokes.  Diabetes is caused in people due to being overweight, large amounts of drinking alcohol, smoking, obese nutrition transition, having increasingly unhealthy lifestyles, and having poor nutrition. In addition, sudden change in the lifestyle of rural people is the reason for metabolic disorders, which results in diabetes. This results in people being more concentrated on health and taking diabetes treatment.

Growing R&D activities is another key factor supporting the growth rate of the diabetic treatment market in the Asia-Pacific. Researchers have found that diabetes is mainly caused by obesity. Therefore, rising insulin therapy also goes to the diabetes treatment market. Insulin is most used by people who have high diabetes. It is used to maintain the sugar levels in the blood.

On the other hand, lack of awareness regarding the treatment options, lack of insurance plans, and increasing cost of diabetes treatment hamper the growth of the diabetes treatment market in Asia-Pacific. In addition, side effects associated with diabetes treatment options further inhibit the market's growth rate. For instance, headaches, cough, dizziness, dry mouth, and abnormal rise in blood sugar are some of the side effects caused by diabetes medication.

This research report on the APAC diabetes treatment market has been segmented and sub-segmented into the following categories.

By Drug Class:

• Insulin
• DPP-4 Inhibitors
• GLP-1 Receptor Agonists
• SGLT2 Inhibitors

By Diabetes Type:

• Type-1
• Type-2

By Distribution Channel:

• Online pharmacies
• Hospital Pharmacies
• Retail Pharmacies

By Country:

• India
• China
• Japan
• South Korea
• Australia
• New Zealand
• Thailand
• Malaysia
• Vietnam
• Philippines
• Indonesia

• Singapore
• Rest of APAC

Geographically, the APAC diabetes treatment market is the fastest-growing regional market in the global market. In Asia Pacific, 250 million people have type 2 diabetes. This type of diabetes is seen in most adults and, in a few cases, in children. The increase of diabetes peaks at 60-69 years of age in Asian people, whereas in the Chinese population, it is high at 79-89 years. India and China account for the most significant portion of Asia. More than fifty percent of people in Asia live with diabetes. Diabetes patients in Asia are more likely to have cardiovascular disease, including macrovascular problems. In South Asian people, diabetes is the second largest cause of death, resulting in increasing diabetes treatments in the region.

In 2021, the Chinese diabetes treatment market accounted for a substantial share of the Asia-Pacific market. China launched public health campaigns encouraging healthy habits, including quitting smoking, eating healthily, and exercising to prevent diabetes. Unfortunately, as a result, the increasing incidence of prediabetes was also higher among the Chinese people. Initiatives such as programs are accelerating the diabetes treatment market in China.

The diabetes treatment market in India is growing significantly. In India, the market for diabetes treatment is majorly driven by the increased prevalence of diabetes, rising obesity, unhealthy diet, behavioral habits, and overweight in many people. Over the last several years, India's diabetes rate has increased significantly. The transformation from euglycemia to prediabetes and diabetes contributes to the increased incidence of diabetes. Researchers in India found that the increase in diabetes is also due to genetic predisposition. Indian Yoga Association started to research diabetes mellitus in India in 2017. India has launched several diabetes awareness programs to take care of people with diabetes, driving the market forward. The rapid increase in fast-food exposure in Indian result in an increase in the risk of diabetes.

On the other hand, the Japanese diabetes treatment market is also anticipated to showcase a healthy CAGR during the forecast period. The incidence of type 2 diabetes in Japan has increased to around 15%. In addition, more than 12 million Japanese people are thought to have excessive sugar levels related to sedentary lifestyles and increased fat consumption. In Japan, everyone is insured for their health. In addition, medical facilities create insurance claims for specific people to treat people with diabetes every month. All these factors drive the diabetes treatment market in Japan.

KEY MARKET PLAYERS:

Novo Nordisk A/S, Sanofi, Merck & Co., Inc., Eli Lilly and Company, AstraZeneca, Takeda Pharmaceutical Company Limited, Boehringer Ingelheim International GmbH, Novartis AG, Johnson & Johnson Services, Inc., and Bayer AG are a few of the companies dominating the diabetes treatment market in the APAC region.